Which has stronger valuation & earnings, RMD or MEDP?

ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.65B 5.86 $1.52B $10.43 22.01 Medpace $2.53B 6.84 $451.12M $17.06 36.37

Is RMD or MEDP more profitable?

ResMed has a net margin of 26.94% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 26.94% 25.58% 18.89% Medpace 17.67% 110.15% 24.84%

Does the media refer more to RMD or MEDP?

In the previous week, ResMed had 7 more articles in the media than Medpace. MarketBeat recorded 18 mentions for ResMed and 11 mentions for Medpace. Medpace's average media sentiment score of 1.40 beat ResMed's score of 0.95 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RMD or EHC more profitable?

ResMed has a net margin of 26.94% compared to Encompass Health's net margin of 10.01%. ResMed's return on equity of 25.58% beat Encompass Health's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 26.94% 25.58% 18.89% Encompass Health 10.01% 18.08% 8.22%

Does the media prefer RMD or EHC?

In the previous week, ResMed had 12 more articles in the media than Encompass Health. MarketBeat recorded 18 mentions for ResMed and 6 mentions for Encompass Health. Encompass Health's average media sentiment score of 1.31 beat ResMed's score of 0.95 indicating that Encompass Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Encompass Health 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, HIMS or RMD?

ResMed has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hims & Hers Health $2.35B 2.77 $128.37M -$0.63 N/A ResMed $5.65B 5.86 $1.52B $10.43 22.01

Is HIMS or RMD more profitable?

ResMed has a net margin of 26.94% compared to Hims & Hers Health's net margin of -5.51%. ResMed's return on equity of 25.58% beat Hims & Hers Health's return on equity. Company Net Margins Return on Equity Return on Assets Hims & Hers Health -5.51% -6.51% -1.20% ResMed 26.94% 25.58% 18.89%

Does the media prefer HIMS or RMD?

In the previous week, Hims & Hers Health had 27 more articles in the media than ResMed. MarketBeat recorded 45 mentions for Hims & Hers Health and 18 mentions for ResMed. ResMed's average media sentiment score of 0.95 beat Hims & Hers Health's score of 0.15 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 3 Very Positive mention(s) 6 Positive mention(s) 34 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ResMed 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, RMD or ISRG?

Intuitive Surgical has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.65B 5.86 $1.52B $10.43 22.01 Intuitive Surgical $10.06B 13.24 $2.86B $8.73 43.20

Does the media prefer RMD or ISRG?

In the previous week, Intuitive Surgical had 9 more articles in the media than ResMed. MarketBeat recorded 27 mentions for Intuitive Surgical and 18 mentions for ResMed. ResMed's average media sentiment score of 0.95 beat Intuitive Surgical's score of 0.68 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intuitive Surgical 13 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, MDT or RMD?

Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medtronic $36.36B 3.30 $4.80B $4.06 23.09 ResMed $5.65B 5.86 $1.52B $10.43 22.01

Is MDT or RMD more profitable?

ResMed has a net margin of 26.94% compared to Medtronic's net margin of 13.93%. ResMed's return on equity of 25.58% beat Medtronic's return on equity. Company Net Margins Return on Equity Return on Assets Medtronic 13.93% 14.78% 7.97% ResMed 26.94% 25.58% 18.89%

Does the media prefer MDT or RMD?

In the previous week, Medtronic had 26 more articles in the media than ResMed. MarketBeat recorded 44 mentions for Medtronic and 18 mentions for ResMed. Medtronic's average media sentiment score of 0.96 beat ResMed's score of 0.95 indicating that Medtronic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medtronic 26 Very Positive mention(s) 7 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ResMed (RMD) Competitors

$229.56 +6.57 (+2.95%)

Closing price 03:59 PM Eastern

Extended Trading

$229.64 +0.08 (+0.04%)

As of 07:52 PM Eastern

Compare

RMD vs. MEDP, EHC, HIMS, ISRG, and MDT

Should you buy ResMed stock or one of its competitors? ResMed's main competitors and comparable companies include Medpace (MEDP), Encompass Health (EHC), Hims & Hers Health (HIMS), Intuitive Surgical (ISRG), and Medtronic (MDT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does ResMed compare to Medpace?

ResMed (NYSE:RMD) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

55.0% of ResMed shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.7% of ResMed shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.65B	5.86	$1.52B	$10.43	22.01
Medpace	$2.53B	6.84	$451.12M	$17.06	36.37

In the previous week, ResMed had 7 more articles in the media than Medpace. MarketBeat recorded 18 mentions for ResMed and 11 mentions for Medpace. Medpace's average media sentiment score of 1.40 beat ResMed's score of 0.95 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	11 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

ResMed currently has a consensus price target of $241.69, indicating a potential upside of 5.28%. Medpace has a consensus price target of $595.20, indicating a potential downside of 4.07%. Given ResMed's stronger consensus rating and higher possible upside, analysts clearly believe ResMed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

ResMed has a net margin of 26.94% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	26.94%	25.58%	18.89%
Medpace	17.67%	110.15%	24.84%

Summary

Medpace beats ResMed on 9 of the 16 factors compared between the two stocks.

How does ResMed compare to Encompass Health?

ResMed (NYSE:RMD) and Encompass Health (NYSE:EHC) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

55.0% of ResMed shares are owned by institutional investors. Comparatively, 97.3% of Encompass Health shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 1.8% of Encompass Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ResMed has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Encompass Health has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

ResMed has a net margin of 26.94% compared to Encompass Health's net margin of 10.01%. ResMed's return on equity of 25.58% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	26.94%	25.58%	18.89%
Encompass Health	10.01%	18.08%	8.22%

ResMed has higher earnings, but lower revenue than Encompass Health. Encompass Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.65B	5.86	$1.52B	$10.43	22.01
Encompass Health	$5.94B	2.02	$566.20M	$6.14	19.84

In the previous week, ResMed had 12 more articles in the media than Encompass Health. MarketBeat recorded 18 mentions for ResMed and 6 mentions for Encompass Health. Encompass Health's average media sentiment score of 1.31 beat ResMed's score of 0.95 indicating that Encompass Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	11 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Encompass Health	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed presently has a consensus target price of $241.69, suggesting a potential upside of 5.28%. Encompass Health has a consensus target price of $146.83, suggesting a potential upside of 20.57%. Given Encompass Health's stronger consensus rating and higher possible upside, analysts clearly believe Encompass Health is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44
Encompass Health	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.2%. Encompass Health pays an annual dividend of $0.76 per share and has a dividend yield of 0.6%. ResMed pays out 25.3% of its earnings in the form of a dividend. Encompass Health pays out 12.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has raised its dividend for 13 consecutive years and Encompass Health has raised its dividend for 2 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

ResMed beats Encompass Health on 12 of the 20 factors compared between the two stocks.

How does ResMed compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and ResMed (NYSE:RMD) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

ResMed has a net margin of 26.94% compared to Hims & Hers Health's net margin of -5.51%. ResMed's return on equity of 25.58% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-5.51%	-6.51%	-1.20%
ResMed	26.94%	25.58%	18.89%

Hims & Hers Health currently has a consensus price target of $32.43, suggesting a potential upside of 16.34%. ResMed has a consensus price target of $241.69, suggesting a potential upside of 5.28%. Given Hims & Hers Health's higher probable upside, research analysts plainly believe Hims & Hers Health is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44

Hims & Hers Health has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market. Comparatively, ResMed has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

In the previous week, Hims & Hers Health had 27 more articles in the media than ResMed. MarketBeat recorded 45 mentions for Hims & Hers Health and 18 mentions for ResMed. ResMed's average media sentiment score of 0.95 beat Hims & Hers Health's score of 0.15 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	3 Very Positive mention(s)	6 Positive mention(s)	34 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ResMed	11 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by insiders. Comparatively, 0.7% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ResMed has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.77	$128.37M	-$0.63	N/A
ResMed	$5.65B	5.86	$1.52B	$10.43	22.01

Summary

ResMed beats Hims & Hers Health on 11 of the 16 factors compared between the two stocks.

How does ResMed compare to Intuitive Surgical?

ResMed (NYSE:RMD) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

In the previous week, Intuitive Surgical had 9 more articles in the media than ResMed. MarketBeat recorded 27 mentions for Intuitive Surgical and 18 mentions for ResMed. ResMed's average media sentiment score of 0.95 beat Intuitive Surgical's score of 0.68 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	11 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intuitive Surgical	13 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Intuitive Surgical has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.65B	5.86	$1.52B	$10.43	22.01
Intuitive Surgical	$10.06B	13.24	$2.86B	$8.73	43.20

55.0% of ResMed shares are held by institutional investors. Comparatively, 83.6% of Intuitive Surgical shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 0.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ResMed has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Intuitive Surgical has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

ResMed currently has a consensus target price of $241.69, indicating a potential upside of 5.28%. Intuitive Surgical has a consensus target price of $508.68, indicating a potential upside of 34.87%. Given Intuitive Surgical's stronger consensus rating and higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44
Intuitive Surgical	1 Sell rating(s)	8 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.68

Intuitive Surgical has a net margin of 28.45% compared to ResMed's net margin of 26.94%. ResMed's return on equity of 25.58% beat Intuitive Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	26.94%	25.58%	18.89%
Intuitive Surgical	28.45%	16.91%	14.83%

Summary

Intuitive Surgical beats ResMed on 11 of the 16 factors compared between the two stocks.

How does ResMed compare to Medtronic?

Medtronic (NYSE:MDT) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.1%. ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.2%. Medtronic pays out 70.9% of its earnings in the form of a dividend. ResMed pays out 25.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has raised its dividend for 49 consecutive years and ResMed has raised its dividend for 13 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Medtronic currently has a consensus target price of $103.92, suggesting a potential upside of 10.87%. ResMed has a consensus target price of $241.69, suggesting a potential upside of 5.28%. Given Medtronic's stronger consensus rating and higher probable upside, analysts clearly believe Medtronic is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medtronic	0 Sell rating(s)	9 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.68
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44

Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medtronic	$36.36B	3.30	$4.80B	$4.06	23.09
ResMed	$5.65B	5.86	$1.52B	$10.43	22.01

ResMed has a net margin of 26.94% compared to Medtronic's net margin of 13.93%. ResMed's return on equity of 25.58% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medtronic	13.93%	14.78%	7.97%
ResMed	26.94%	25.58%	18.89%

Medtronic has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, ResMed has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

82.1% of Medtronic shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 0.3% of Medtronic shares are owned by insiders. Comparatively, 0.7% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Medtronic had 26 more articles in the media than ResMed. MarketBeat recorded 44 mentions for Medtronic and 18 mentions for ResMed. Medtronic's average media sentiment score of 0.96 beat ResMed's score of 0.95 indicating that Medtronic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medtronic	26 Very Positive mention(s)	7 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	11 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Medtronic beats ResMed on 11 of the 19 factors compared between the two stocks.

Get ResMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RMD vs. The Competition

Export

Metric	ResMed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$32.17B	$5.55B	$7.21B	$23.26B
Dividend Yield	1.18%	1.79%	2.56%	3.58%
P/E Ratio	22.01	20.89	213.15	24.63
Price / Sales	5.86	72.23	652.32	20.42
Price / Cash	17.24	32.78	77.71	34.34
Price / Book	5.06	5.99	10.37	4.69
Net Income	$1.52B	$150.13M	$3.49B	$1.07B
7 Day Performance	3.78%	-2.23%	-2.20%	-2.41%
1 Month Performance	2.25%	-3.84%	-0.38%	-4.27%
1 Year Performance	-15.41%	10.26%	19.16%	8.87%

ResMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RMD ResMed	3.8518 of 5 stars	$229.56 +2.9%	$241.69 +5.3%	-17.6%	$32.17B	$5.65B	22.01	11,370	Positive News Analyst Upgrade
MEDP Medpace	2.6626 of 5 stars	$591.29 flat	$595.20 +0.7%	+21.4%	$16.50B	$2.53B	34.66	6,200	Positive News Analyst Forecast
EHC Encompass Health	4.8123 of 5 stars	$121.80 +0.0%	$148.71 +22.1%	-2.7%	$12.02B	$5.94B	19.84	42,000	Positive News
HIMS Hims & Hers Health	2.7513 of 5 stars	$27.66 -0.2%	$32.50 +17.5%	-48.1%	$6.47B	$2.35B	N/A	2,442	Trending News
ISRG Intuitive Surgical	4.4698 of 5 stars	$366.70 flat	$508.68 +38.7%	-16.0%	$129.55B	$10.06B	42.00	17,021	Trending News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RMD) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Competitors

RMD vs. MEDP, EHC, HIMS, ISRG, and MDT

How does ResMed compare to Medpace?

Summary

How does ResMed compare to Encompass Health?

Summary

How does ResMed compare to Hims & Hers Health?

Summary

How does ResMed compare to Intuitive Surgical?

Summary

How does ResMed compare to Medtronic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RMD vs. The Competition

ResMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ResMed (RMD) Competitors

RMD vs. MEDP, EHC, HIMS, ISRG, and MDT

How does ResMed compare to Medpace?

Do insiders and institutionals believe in RMD or MEDP?

Which has stronger valuation & earnings, RMD or MEDP?

Does the media refer more to RMD or MEDP?

Which has more volatility & risk, RMD or MEDP?

Do analysts rate RMD or MEDP?

Is RMD or MEDP more profitable?

Summary

How does ResMed compare to Encompass Health?

Do institutionals & insiders have more ownership in RMD or EHC?

Which has more risk & volatility, RMD or EHC?

Is RMD or EHC more profitable?

Which has preferable valuation and earnings, RMD or EHC?

Does the media prefer RMD or EHC?

Do analysts prefer RMD or EHC?

Is RMD or EHC a better dividend stock?

Summary

How does ResMed compare to Hims & Hers Health?

Is HIMS or RMD more profitable?

Do analysts prefer HIMS or RMD?

Which has more risk & volatility, HIMS or RMD?

Does the media prefer HIMS or RMD?

Do institutionals & insiders hold more shares of HIMS or RMD?

Which has better earnings and valuation, HIMS or RMD?

Summary

How does ResMed compare to Intuitive Surgical?

Does the media prefer RMD or ISRG?

Which has preferable valuation & earnings, RMD or ISRG?

Do insiders and institutionals have more ownership in RMD or ISRG?

Which has more risk and volatility, RMD or ISRG?

Do analysts rate RMD or ISRG?

Is RMD or ISRG more profitable?

Summary

How does ResMed compare to Medtronic?

Is MDT or RMD a better dividend stock?

Do analysts rate MDT or RMD?

Which has stronger valuation & earnings, MDT or RMD?

Is MDT or RMD more profitable?

Which has more volatility & risk, MDT or RMD?

Do insiders and institutionals hold more shares of MDT or RMD?

Does the media prefer MDT or RMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RMD vs. The Competition

ResMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools